Abbott's MitraClip Class I Recall Results From Delivery Snafus
This article was originally published in The Gray Sheet
Executive Summary
Abbott plans to require additional training for physicians implanting the mitral valve repair device and to add a new warning to the device’s labeling after nine instances in which users could not properly deploy the system.
You may also be interested in...
MitraClip Medicare Gains: National Coverage Follows Bonus Payment Decision
CMS finalized a national coverage determination for transcatheter mitral valve repair, conditioned on a registry and on minimum facility and experience requirements for hospitals. The policy follows close behind a new-technology add-on payment granted to Abbott’s MitraClip device.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.